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Conclusions: – Patients with OA of the knee which is associated
with mechanical symptoms are more likely to achieve subjective
improvement after knee arthroscopy.
– Knee arthroscopy for OA may be reserved only for patients
with preoperative mechanical symptoms.
– More prospective randomised placebo-controlled studies com-
paring both groups are required.
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Purpose: To study the association of socio-demographic and
comorbidity factors with functional limitation in veterans with
osteoarthritis.
Methods: We mailed a survey to all veterans receiving health
care at Upper Midwest Veterans Affairs (VA) Network with an
in- or out-patient encounter between 10/1/96 and 3/31/98. The
survey included Short-Form 36 for veterans (SF36V, a validated
version of SF-36) and questions related to functional limitation
as measured by limitation of six Activities of Daily Living (ADLs;
bathing, dressing, eating, transfer from chair, walking, and toi-
leting), demographics and current smoking status. Patients with
osteoarthritis were identified by the presence of International
Classification of Diseases (ICD)-9 code (715.xx) for diagnosis for
osteoarthritis in VA databases. In- and out-patient health care
utilization (in post-survey year) and comorbidity data using ICD-9
codes were also obtained.
The main predictors of interest were socio-demographic and
comorbidity characteristics. The outcomes of interest were: mod-
erate (1-2 ADLs) or severe ADL (≥3 ADLs) limitation (no ADL
as reference category); any inpatient visit (none as reference
category); and being in the highest quartile of outpatient visits
(other quartiles as reference category). Unadjusted estimates
using t-test and chi-square tests and adjusted odds ratios using
multivariable logistic regression analyses were obtained.
Results: The survey response rate was 58% (40,508/70,334).
7,342 (10%) had an ICD-9 code for osteoarthritis. The mean age
(±standard deviation) was 67±13 years, 96% were men, 95%
were Caucasian. Data on ADL limitation was available for 4,796
subjects (65%). ADL limitation was absent in 25%, moderate in
41% and severe in 34%.
Employment status, marital status and COPD/asthma were as-
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Moderate ADL Limitation Severe ADL Limitation Inpatient Utilization Outpatient Utilization
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Age (in years) 1 (1.0, 1.0) 0.52 1.0 (1.0, 1.0) 0.46 1.0 (1.0, 1.0) 0.001 1.0 (1.0, 1.0) 0.014
Education 0.11 0.04 0.9 0.002
<8th grade 1.3 (1.0, 1.7) 1.2 (1.0, 1.6) 1.2 (1.0, 1.6) 1.0 (0.8, 1.2) 0.7 (0.5, 0.8)
Some high school 1.1 (0.8, 1.4) 1.0 (0.7, 1.3) 1.0 (0.7, 1.3) 0.9 (0.7, 1.1) 1.0 (0.7, 1.2)
High school Graduate 1.0 (0.8, 1.2) 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 1.0 (0.8, 1.2) 0.8 (0.7, 1.0)
Employment status 0.015 <0.001 0.026 <0.001
Unemployed 1.5 (1.1, 1.9) 2.3 (1.7, 3.0) 2.3 (1.7, 3.0) 1.4 (1.1, 1.8) 1.5 (1.2, 2.0)
Retired 1.2 (1.0, 1.5) 1.3 (1.0, 1.6) 1.3 (1.0, 1.6) 1.4 (1.1, 1.7) 1.3 (1.1, 1.6)
Unknown 1.7 (1.0, 3.0) 1.9 (1.1, 3.3) 1.9 (1.1, 3.3) 1.4 (0.8, 2.4) 0.8 (0.5, 1.3)
Not married 0.8 (0.7, 1.0) 0.04 0.9 (0.8, 1.1) 0.45 1.5 (1.3, 1.8) <0.001 1.1 (1.0, 1.3) 0.12
Male gender 1.2 (0.9, 1.6) 0.26 1.8 (1.2, 2.7) 0.006 0.9 (0.6, 1.3) 0.44 1.1 (0.7, 1.5) 0.72
Current smoker 1.1 (0.9, 1.3) 0.46 1.2 (0.9, 1.5) 0.17 1.1 (0.9, 1.3) 0.50 0.9 (0.7, 1.1) 0.25
COPD/asthma 1.3 (1.1, 1.6) 0.012 1.6 (1.3, 2.0) <0.001 1.8 (1.5, 2.1) <0.001 1.6 (1.3, 1.9) <0.001
Depression 1.0 (0.7, 1.2) 0.76 1.6 (1.3, 2.1) <0.001 1.9 (1.5, 2.3) <0.001 3.2 (2.6, 4.1) <0.001
Diabetes 1.2 (0.9, 1.4) 0.15 1.4 (1.1, 1.7) 0.005 1.2 (1.0, 1.4) 0.07 1.9 (1.6, 2.3) <0.001
Hypertension 1.1 (0.9, 1.3) 0.25 1.0 (0.8, 1.1) 0.67 1.2 (1.0, 1.4) 0.021 1.2 (1.0, 1.4) 0.015
Heart Disease 1.1 (0.9, 1.4) 0.27 1.1 (0.9, 1.4) 0.27 1.5 (1.2, 1.8) <0.001 1.6 (1.3, 1.9) <0.001
sociated with moderate ADL limitation, while COPD/asthma, de-
pression, diabetes, gender and education were associated with
severe ADL limitation (Table 1).
Age, employment status, marital status, COPD/asthma, depres-
sion, hypertension or heart disease were associated with inpa-
tient use. Age, employment status, education level, and all five
comorbidities were associated with higher outpatient use (Table
1).
Race was not significantly associated with any outcome
Reference categories: Education - College & beyond; Employ-
ment - employed; Marital - married: gender - female
Conclusions: Various comorbidity and demographic factors are
associated with functional status and health care utilization in
patients with osteoarthritis. It is conceivable that better manage-
ment of comorbidities in these patients may improve functional
status and decrease utilization.
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Purpose: To compare the efficacy and safety of Nimesulide ER
200 mg vs. Diclofenac SR 100 mg in patients with osteoarthritis
knee.
Methods: 262 patients aged > 45 years diagnosed to have
osteoarthritis (OA) of knee were randomized (1:1) in this mul-
ticentric study across India. Peptic ulcer disease; compromised
renal/hepatic/cardiovascular function; hematological disease or
bleeding disorders; history of allergy or hypersensitivity to
NSAIDs; pregnancy and lactation were regarded as exclusion.
Patients were allocated to receive either Willgo® (n = 131) or
Voveran SR® (n = 131) tablet as per computer generated ran-
domization once daily for a study treatment period of 30 days.
Protocol assessment visits were on days 15 and 30. Primary effi-
cacy endpoint was evaluated using VAS (Visual Analogue Scale)
of 10 cm for pain at baseline, day 1 (multiple time points), day 15
